Research
Hormonal
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduced the risk of any cardiovascular event in overweight or obese adults without diabetes.
GLP-1 RA can be considered for reducing cardiovascular risk in overweight or obese patients without diabetes.
StrongSupportsmedium confidence
In overweight or obese adults without diabetes, treatment with GLP-1 RA reduced the risk of cardiovascular events.
Why this rating
Based on a meta-analysis of placebo-controlled randomized controlled trials.
Source
Effect of glucagon‐like peptide‐1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta‐analysis of placebo‐controlled randomized trials
Ana Rita Leite et al. · Diabetes Obesity and Metabolism · 2022
DOI 10.1111/dom.14707
Meta-analysisCited 34×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →